Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13122MR)

This product GTTS-WQ13122MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13122MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12003MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ15946MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12145MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ6609MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ4208MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ4353MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ12711MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ8995MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW